Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Nov 13 - Nov 18
The class-wide presence of the thyroid warning reflects regulatory consistency rather than specific evidence against any individual medication
Took a bit longer to arrive than expected
doi: 10.1016/j.bbamcr.2010.10.007
Molecular Identity Developer Innovent Biologics (China) / Eli Lilly partnership Mechanism Dual GLP-1 and glucagon receptor agonist GIP Activation No Administration Weekly subcutaneous Development Stage Phase 3 trials (primarily in China) Glucagon Receptor Pathway The glucagon receptor activation in Mazdutide engages metabolic pathways distinct from GIP: Hepatic metabolism: Glucagon signaling activates liver-based energy expenditure pathways Thermogenesis: Documented effects on energy expenditure in preclinical models Lipid metabolism: Research indicates effects on liver lipid processing Different satiety mechanism: Complementary to GLP-1's central appetite effects Published Research Mazdutide clinical data has been published primarily from Chinese trial populations: Trial Phase Population Key Findings GLORY-1 Phase 3 Chinese adults Metabolic endpoints documented GLORY-2 Phase 3 Chinese adults Glycemic pathway effects documented IBI362 Phase 2 Phase 2 Multiple cohorts Dose-response relationships established Tirzepatide: GLP-1 + GIP Tirzepatide represents the most established dual-agonist compound with full FDA approval and extensive published literature
US$ 22.75
US$ 27.69
US$ 25.92
US$ 20.75
US$ 23.86
US$ 28.74
US$ 28.62
US$ 28.63
